Taiwan,
April 2017
This report offers companies, investors, policymakers, and stakeholders crucial insight into five companies at the cutting edge of Taiwan’s biotech industry: PharmaEngine, PharmaEssentia, OBI Pharma, SyneuRx, and TaiGen Biotechnology.
The report features in-depth exclusive interviews with the heads of these pioneering organizations, facts and figures on the companies’ market capitalizations, therapeutic areas, and product pipelines, as well as commentary from leading KOLs on why these particular organizations are worthy of greater international attention. Also included in the report is a comprehensive introduction to Taiwan’s biotech industry and its importance under the administration of President Tsai Ing-Wen.
This report offers companies, investors, policymakers, and stakeholders crucial insight into five companies at the cutting edge of Taiwan’s biotech industry: PharmaEngine, PharmaEssentia, OBI Pharma, SyneuRx, and TaiGen Biotechnology.
The report features in-depth exclusive interviews with the heads of these pioneering organizations, facts and figures on the companies’ market capitalizations, therapeutic areas, and product pipelines, as well as commentary from leading KOLs on why these particular organizations are worthy of greater international attention. Also included in the report is a comprehensive introduction to Taiwan’s biotech industry and its importance under the administration of President Tsai Ing-Wen.
